The Mergers and Acquisitions (M&A) landscape in Vietnam’s pharmaceutical sector has seen new developments as Lian SGP Holding Pte. Ltd (a subsidiary of Livzon Pharmaceutical Group, China) proceeds with legal steps to increase its ownership in Imexpharm Pharmaceutical Joint Stock Company (Stock code: IMP).
Transaction details According to updates from securities regulators in early March 2026, the buyer submitted a public bid for over 120 million IMP shares. This volume represents approximately 77.94% of the target company’s charter capital. With a proposed price of about 57,400 VND per share, the total transaction value is estimated at 6,900 billion VND. If successful, this deal will lead to a significant shift in Imexpharm’s shareholder structure, granting controlling power to the foreign investor.
Corporate and market context Livzon Pharmaceutical is a large-scale entity established in 1985 and listed on multiple stock exchanges. Imexpharm, the target company, is a prominent local manufacturer with facilities meeting EU-GMP standards, specializing in antibiotics and specialized treatment products. Previously, national competition authorities approved this economic concentration under specific conditions regarding the maintenance of supply stability and non-discriminatory distribution of active pharmaceutical ingredients in the Vietnamese market.
Industry trends This movement is part of a broader trend of ownership transition within the healthcare and pharmaceutical industries. Recently, several domestic medical systems, pharmacy retail chains, and manufacturing plants have consistently attracted capital from international investment funds and corporations such as Ares Management, Quadria Capital, and Creador, pushing industry valuations to significant levels.